Royalty Pharma PLC
F:RPD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
F:RPD
|
US |
|
5
|
5E Advanced Materials Inc
ASX:5EA
|
US |
|
K
|
Karman Holdings Inc
NYSE:KRMN
|
US |
|
Tesoro Resources Ltd
ASX:TSO
|
AU |
|
Aures Technologies SA
F:A5R
|
FR |
|
Hino Motors Ltd
TSE:7205
|
JP |
|
CTS Corp
NYSE:CTS
|
US |
|
Af Gruppen ASA
OTC:AGRUF
|
NO |
|
Danske Bank A/S
CSE:DANSKE
|
DK |
|
P
|
Pick N Pay Stores Ltd
JSE:PIK
|
ZA |
|
Eupraxia Pharmaceuticals Inc
NASDAQ:EPRX
|
CA |
|
J
|
Japan Pure Chemical Co Ltd
TSE:4973
|
JP |
|
Financiere de Tubize SA
LSE:0D53
|
BE |
Wall St Price Targets
RPD Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for RPD is 34.95 EUR with a low forecast of 27.81 EUR and a high forecast of 41.49 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RPD's stock price target?
Price Target
34.95
EUR
According to Wall Street analysts, the average 1-year price target for RPD is 34.95 EUR with a low forecast of 27.81 EUR and a high forecast of 41.49 EUR.
What is the Revenue forecast for Royalty Pharma PLC?
Projected CAGR
16%
Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 16%.
What is the Operating Income forecast for Royalty Pharma PLC?
Projected CAGR
12%
Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 12%.
What is the Net Income forecast for Royalty Pharma PLC?
Projected CAGR
31%
Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 7 years is 31%.
